SCHEMBL5084292

SCHEMBL5084292

COc1cc(O)c(C(=O)C=Cc2ccc(O)c(OC)c2)c(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 1.00
MAPT P10636 5/20 1.00
KMT2A Q03164 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
KDM4E B2RXH2 2/20 1.00
MEN1 O00255 2/20 1.00
HPGD P15428 2/20 1.00
MCL1 Q07820 1/20 1.00
ABCG2 Q9UNQ0 6/20 0.85
TP53 P04637 2/20 0.81
USP2 O75604 1/20 0.81
ALDH1A1 P00352 1/20 0.81
ALOX15 P16050 1/20 0.81
MAPK1 P28482 1/20 0.81
NFKB1 P19838 1/20 0.81
DPP4 P27487 1/20 0.81
NFKB2 Q00653 1/20 0.81
RELA Q04206 1/20 0.81
ATM Q13315 1/20 0.74
HSD17B10 Q99714 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5084287 1.00 CYP3A4 (1.00) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL30383925 1.00 CYP3A4 (1.00) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL5088532 0.95 TDP1 (0.90) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL30384102 0.95 TDP1 (0.90) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL25265249 0.95 MAPT (0.90) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL25195888 0.95 MAPT (0.90) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL5088525 0.95 TDP1 (0.90) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL25195035 0.92 ABCG2 (1.00) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL5432735 0.92 ABCG2 (1.00) CYP3A4MAPTKMT2ATDP1KDM4E
SCHEMBL25196877 0.92 CYP3A4 (0.85) CYP3A4MAPTKMT2ATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-9200046-B2 Reporter system for high throughput screening of compounds and uses thereof CORNELL UNIVERSITY (US) 2015-12-01 US disclosed
US-20130005666-A1 REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF CORNELL UNIVERSITY (US) 2013-01-03 US disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed
US-4605674-A VIRICIDES HOFFMANN-LA ROCHE INC. (US) 1986-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 CYP3A4 17/4885MAPT 4566/4885KMT2A 4362/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CYP3A4 928/4885MAPT 3297/4885KMT2A 2792/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CYP3A4 1589/4885MAPT 3512/4885KMT2A 3188/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CYP3A4 1589/4885MAPT 3512/4885KMT2A 3188/4885
US-20130005666-A1 REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF NFE2, NFE2L2, UBE2N CYP3A4 2576/4885MAPT 1707/4885KMT2A 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.